Antithymocyte immunoglobulin (rabbit)

Generic Name: Antithymocyte immunoglobulin (rabbit)

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 308067-60-9

Unique Ingredient Identifier: D7RD81HE4W

Background: Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.

Indication: For prevention of renal transplant rejection

Associated Conditions: Rejection Acute Renal

Associated Therapies: -

Clinical Trials

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

Phase 3

Withdrawn

Conditions: Cardiac Allograft Vasculopathy

Interventions: Drug: Thymoglobulin

First Posted Date: 2010-07-08

Last Posted Date: 2019-03-14

Lead Sponsor: Cedars-Sinai Medical Center

Registration Number: NCT01157949

Locations: 🇺🇸
Cedars-Sinai Medical Center, Beverly Hills, California, United States

Hematopoietic Stem Cell Transplant for Fanconi Anemia

Phase 2

Completed

Conditions: Fanconi Anemia

Interventions: Device: CliniMACs device
Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: ATG

First Posted Date: 2010-02-19

Last Posted Date: 2019-09-11

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 1

Registration Number: NCT01071239

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: Leukemia
Acute Lymphoblastic Leukemia
Allogeneic Haematopoietic Stem Cell Transplantation
Lymphoma

Interventions: Drug: Busulfan
Drug: Clofarabine
Drug: Thymoglobulin
Procedure: Stem Cell Transplant

First Posted Date: 2009-10-06

Last Posted Date: 2018-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00990249

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pilot Study of Unrelated Cord Blood Transplantation

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Acute
Leukemia, Lymphoblastic, Acute
Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Myelodysplastic Syndromes
Hodgkin Disease

Interventions: Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Melphalan
Radiation: Radiotherapy
Drug: Intravenous busulphan
Drug: Thymoglobulin
Drug: Ciclosporin
Drug: Mycophenolate mofetil (MMF)

First Posted Date: 2009-06-08

Last Posted Date: 2015-02-11

Lead Sponsor: King's College Hospital NHS Trust

Target Recruit Count: 40

Registration Number: NCT00916045

Locations: 🇬🇧
King's College Hosptial NHS Foundation Trust, London, United Kingdom

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Lenalidomide
Drug: Fludarabine
Drug: Rituximab
Procedure: Stem Cell Transplantation
Drug: Thymoglobulin
Drug: Bendamustine
Drug: Allopurinol

First Posted Date: 2009-05-12

Last Posted Date: 2020-01-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT00899431

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists

Not Applicable

Completed

Conditions: End Stage Renal Disease

Interventions: Drug: Daclizumab
Drug: Rabbit Antithymocyte globulin

First Posted Date: 2009-03-10

Last Posted Date: 2016-04-26

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 200

Registration Number: NCT00859131

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Phase 2

Completed

Conditions: Stem Cell Transplantation
Leukemia

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Thymoglobulin
Drug: Azacitidine
Procedure: Stem Cell Transplant

First Posted Date: 2008-12-22

Last Posted Date: 2021-02-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00813124

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Aplastic Anemia

Interventions: Drug: Thymoglobulin
Drug: Cyclosporine
Drug: Methylprednisolone
Drug: G-CSF

First Posted Date: 2008-12-11

Last Posted Date: 2013-03-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00806598

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Phase 1

Terminated

Conditions: Neuroblastoma
Immunodeficiencies
Anemia
Leukemia
Lymphoma

Interventions: Radiation: Total Body Irradiation
Drug: Alemtuzumab
Drug: Busulfan
Drug: Melphalan
Drug: Fludarabine
Drug: Phenytoin
Drug: Rabbit Antithymocyte Globulin
Drug: Cyclophosphamide
Drug: Horse Antithymocyte Globulin
Drug: Thiotepa

First Posted Date: 2008-12-04

Last Posted Date: 2019-03-27

Lead Sponsor: Columbia University

Target Recruit Count: 1

Registration Number: NCT00801931

Locations: 🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation

Phase 2

Completed

Conditions: Diabetes Mellitus, Type I

Interventions: Drug: Low Molecular Weight Sulfated Dextran (LMW-SD)
Drug: Heparin
Drug: CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)
Drug: Prograf® (Tacrolimus) OR Cyclosporine
Drug: Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant
Drug: Simulect® (Basiliximab) - at 2nd or 3rd transplant
Drug: Klexane® (Enoxaparinsodium)
Drug: Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)
Drug: Enbrel® (Etanercept)

First Posted Date: 2008-11-11

Last Posted Date: 2021-09-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00789308

Locations: 🇳🇴
University Hospital Rikshospitalet, Oslo, Norway
🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪
Uppsala University Hospital, Uppsala, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy